Subsidiary of Anavira Health Systems
Psycora is developing Psycoryn (vincexorphine), a next-generation pharmacotherapy for Opioid Use Disorder — a condition that claims over 100,000 American lives each year and has seen no meaningful innovation in standard of care in four decades.
The Treatment Gap
Opioid Use Disorder is one of the most lethal chronic conditions in medicine — yet the pharmacopeia used to treat it has barely evolved since the 1970s. Medication-assisted treatment with buprenorphine, methadone, and naltrexone remains the cornerstone of care, but these agents carry significant limitations that drive the majority of patients out of treatment.
Pipeline
A novel opioid use disorder therapeutic designed to overcome the limitations of current MAT by simultaneously engaging two receptor systems with precise pharmacological bias.
Vincexorphine is a partial agonist at the mu-opioid receptor (MOR) with reduced recruitment of beta-arrestin downstream signaling. This biased agonism profile is designed to provide analgesia and withdrawal suppression with an improved side-effect profile compared to full mu agonists — including reduced respiratory depression risk and lower abuse liability relative to full MOR agonists.
Vincexorphine simultaneously antagonizes the kappa-opioid receptor (KOR), blocking the dysphoric and stress-inducing effects of dynorphin. Elevated KOR activity is implicated in negative affective states, craving, and relapse vulnerability. KOR antagonism as a component of OUD treatment is supported by clinical evidence and represents a key differentiator from existing MAT agents.
| Property | Methadone Full MOR agonist |
Buprenorphine Partial MOR agonist |
Naltrexone Opioid antagonist |
Psycoryn Partial MOR + KOR antagonism |
|---|---|---|---|---|
| MOR activity | Full agonist | Partial agonist | Antagonist | Partial agonist (biased) |
| KOR activity | None | None | None | Antagonist |
| Abuse liability | High | Moderate (CE) | Minimal | Reduced (biased profile) |
| Respiratory depression risk | Significant | Lower | Minimal | Reduced |
| Withdrawal suppression | High | Good | None (requires detox) | Expected |
| Craving reduction (KOR pathway) | Limited | Limited | Moderate | Targeted (KOR block) |
| Administration | Daily DOT | Daily SL (office or home) | Daily oral / Monthly IM | TBD |
| Development stage | Approved 1972 | Approved 2002 | Approved 1984 | Preclinical |
Mechanism
Select the explanation that matches your background.
Opioid use disorder is driven by two complementary biological forces. First, the mu-opioid receptor (MOR) drives the rewarding and pain-relieving effects of opioids — and when the body adapts to chronic opioid use, removing the drug causes severe withdrawal sickness. Second, the kappa-opioid receptor (KOR) becomes overactive during chronic opioid use, producing stress, anxiety, depression, and powerful drug cravings — especially during abstinence.
Current medications only address the first problem. Buprenorphine partially activates the MOR to reduce withdrawal, but it leaves the KOR system untouched — so patients often continue to experience persistent craving, dysphoria, and mood instability that drive relapse.
Psycoryn is designed to solve both problems simultaneously. It is a partial agonist at the MOR — providing withdrawal relief and stabilization — while simultaneously blocking the KOR to reduce craving, stress, and the negative emotional states that make recovery so difficult to maintain.
Think of it as the difference between taking a painkiller that only numbs the pain versus one that also addresses the underlying cause. Both are useful, but one gives patients a substantially better chance of staying in treatment and rebuilding their lives.
Opioid Use Disorder involves dysregulation of both the mesolimbic dopamine reward pathway (mu-opioid receptor) and the dysphoria/aversion circuit (kappa-opioid receptor). Current MAT agents — buprenorphine, methadone, naltrexone — are MOR-directed; none simultaneously address KOR-mediated negative affective symptoms.
Vincexorphine's dual pharmacodynamics — partial MOR agonism with reduced beta-arrestin recruitment, combined with KOR antagonism — are designed to address withdrawal suppression, craving, and stress-induced relapse within a single therapeutic candidate.
The partial agonism at MOR provides a ceiling effect on respiratory depression relative to full agonists, with potential for office-based prescribing without the regulatory burden of methadone programs. The KOR antagonist component addresses the dynorphin-mediated dysphoric state that contributes to treatment dropout and relapse, a mechanism currently unmatched by any approved OUD pharmacotherapy.
Patients experiencing inadequate response to buprenorphine — persistent craving, mood instability, or early treatment discontinuation — represent a particularly relevant target population for a dual MOR/KOR agent.
MOR bias: Vincexorphine is characterized as a partial agonist at the mu-opioid receptor with functional selectivity for G-protein signaling over beta-arrestin recruitment. Preclinical data suggests that beta-arrestin recruitment contributes to respiratory depression, constipation, and the development of analgesic tolerance. Reducing this downstream pathway while retaining MOR-mediated G-protein signaling is expected to provide withdrawal suppression with an improved safety profile relative to full MOR agonists.
KOR antagonism: The dysphoric and anxiogenic effects of opioid withdrawal are partly mediated by elevation of endogenous dynorphin at the KOR. KOR activation potentiates CRF-mediated stress responses, disrupts dopaminergic tone in the NAc, and contributes to the negative reinforcement mechanisms that drive addiction. Antagonism of the KOR by vincexorphine is designed to attenuate these effects, reducing negative reinforcement and improving affective stability during early recovery.
Integration: The convergence of MOR partial agonism (reward stabilization) and KOR antagonism (aversion reduction) is intended to address both positive and negative reinforcement substrates of OUD — a dual-mechanism approach currently unrepresented in the approved MAT landscape.
Vincexorphine is at the computational pharmacology stage of development. Target engagement predictions are derived from structural analogs and literature precedent; in vitro and in vivo validation studies are planned as the next development milestone.
Leadership
Vincent Maldonado is the founder of Psycora, a pharmaceutical company dedicated to developing novel pharmacotherapies for substance use disorders. His path to this work runs through a decade of academic psychology — both clinical and research — followed by an MBA at the University of New Mexico, and now as a medical student at the University of Texas Medical Branch in Galveston, where he continues to deepen his understanding of the neurobiology of addiction.
That trajectory — from understanding how addiction works in the brain, to building the business infrastructure to bring a drug to market — is the engine behind Psycora. Vince saw firsthand in his clinical training that existing treatments were fundamentally limited: they suppressed withdrawal but left the dysphoric, craving-driven core of addiction untreated. He set out to change that.
In parallel with his MD training, Vince is developing Psycoryn (vincexorphine) — a dual-mechanism OUD therapeutic with biased mu-opioid partial agonism and kappa-opioid receptor antagonism — representing the first novel mechanism of action proposed for OUD treatment in over four decades.
He founded Psycora under Anavira Health Systems, Inc., a Texas-based holding company developing a portfolio of CNS and psychiatric therapeutics. The subsidiary structure reflects a deliberate strategy: keeping Psycora focused on a specific pipeline asset while the parent company builds the infrastructure for a broader CNS portfolio.
Corporate Structure
Psycora operates as a subsidiary of Anavira Health Systems, Inc., a Texas-based holding company developing a portfolio of CNS and psychiatric therapeutics. The subsidiary structure allows focused pipeline development while leveraging shared infrastructure and governance.